(Q40612376)

22 September 2017

Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells (English)

1 reference

22 September 2017

multiple drug resistance

1 reference

3

Branimir I Sikic

1 reference

22 September 2017

Norman J Lacayo

1

1 reference

PubMed ID

14641819

22 September 2017

George E Duran

series ordinal

2

1 reference

22 September 2017

1 May 2003

1 reference

Journal of Experimental Therapeutics & Oncology

22 September 2017

1 reference

22 September 2017

3

1 reference

22 September 2017

3

1 reference

22 September 2017

127-135

1 reference

Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.

22 September 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Improved treatment results in children with AML: Results of study AML-BFM 93

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1359-4117.2003.01088.X

10.1046/J.1359-4117.2003.01088.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

14641819